Impact of extended-spectrum chromosomal AmpC (ESAC) of Escherichia coli on susceptibility to cefiderocol

Otávio Hallal Ferreira RaroChristophe Le TerrierPatrice NordmannLaurent Poirel1Medical and Molecular Microbiology,Faculty of Science and Medicine,University of Fribourg,Fribourg,Switzerland2Division of Intensive Care Unit,University hospitals of Geneva,Geneva,Switzerland3Swiss National Reference Center for Emerging Antibiotic Resistance (NARA),University of Fribourg,Fribourg,SwitzerlandRafael Vignoli
DOI: https://doi.org/10.1128/spectrum.00704-24
IF: 3.7
2024-06-12
Microbiology Spectrum
Abstract:The impact of chromosomally encoded wild-type or extended-spectrum (ESAC) AmpC β-lactamases of Escherichia coli on susceptibility to ceftazidime, cefepime, and cefiderocol was evaluated in ... We showed here that chromosomally encoded intrinsic extended-spectrum cephalosporinases of Escherichia coli may impact susceptibility not only to ceftazidime and cefepime but also to cefiderocol.
microbiology
What problem does this paper attempt to address?
This paper mainly discusses the impact of the broad-spectrum chromosomal AmpC (ESAC) enzyme in Escherichia coli on the sensitivity of the antibiotic cefiderocol (a new cephalosporin antibiotic with an iron carrier). The study found that although ESAC enzymes typically develop resistance to cefazidime and cefepime, reducing their sensitivity, they can also make cefiderocol their substrate, thereby affecting the efficacy of cefiderocol. This suggests that ESAC enzymes not only affect cefazidime and cefepime but may also affect the antibacterial activity of cefiderocol. The experiment evaluated the influence of ESAC enzyme expression on the minimum inhibitory concentration (MIC) of cefiderocol, cefazidime, and cefepime by constructing recombinant strains of Escherichia coli with different genetic backgrounds, including wild-type, PBP3-modified, and porin-deficient strains. The results showed that the production of ESAC enzyme significantly increased the MIC value of cefiderocol, which was observed in all recombinant strains, although to varying degrees. In addition, the study also found that ESAC enzymes could affect the sensitivity of cefiderocol even in the background of PBP3 sequence variation or porin protein defects. In conclusion, this study reveals the potential resistance of ESAC enzymes in Escherichia coli to the new drug cefiderocol, suggesting that the clinical application of cefiderocol may be affected by resistance produced by these enzymes, providing important information for antibiotic treatment strategies.